Tredaptive 2 000 mg/ 40 mg приложен едновременно със симвастатин в сравнение със самостоятелното приложение на симвастатин или Tredaptive 2 000 mg/ 40 mg за 12 седмици значително понижава LDL- C (- 47, 9%, - 37, 0%, - 17, 0%), TG (съответно - 33, 3%, - 14, 7%, - 21, 6%), apo B (съответно - 41, 0%, - 28, 8%, - 17, 1%), и TC (съответно - 29, 6%, - 24, 9%, - 9, 1%), както и LDL- C:
Lietojot Tredaptive (2000 mg/ 40 mg) vienlaikus ar simvastatīnu, ja salīdzināja ar tikai simvastatīnu vai tikai Tredaptive (2000 mg/ 40 mg), lietojot 12 nedēļas, nozīmīgi pazeminājās ZBL- H (attiecīgi - 47, 9%, - 37, 0%, - 17, 0%), TG (attiecīgi - 33, 3%, - 14, 7%, - 21, 6%), apo B (attiecīgi - 41, 0%, - 28, 8%, - 17, 1%), un KH (attiecīgi - 29, 6%, - 24, 9%, - 9, 1%), kā arī ZBL- H: ABL- H (attiecīgi - 57, 1%, - 39, 8%, - 31, 2%), ne- ABL- H (attiecīgi - 45, 8%, - 33, 4%, - 18, 1%), un KH: ABL- H līmenis (attiecīgi - 43, 0%, - 28, 0%, - 24, 9%) un nozīmīgi pieauga ABL- H līmenis (attiecīgi 27, 5%, 6, 0%, 23, 4%).